Tough Year Ahead For Drug Maker: Lilly said yesterday its profits could fall by as much as 20% this year amid lower projected sales for its antipsychotic drug Zyprexa and general and administrative costs that will be higher than what analysts had estimated, the WSJ reports . Shares in the drug maker closed lower yesterday after it said 2012 earnings would likely be between $3.10 and $3.20 per share, vs. the $3.61 anticipated by analysts surveyed by Thomson Reuters. Dendreon Releases Sales Figures: Shares in Dendreon rose yesterday after the company said its prostate-cancer therapy Provenge racked up $82 million in gross revenue in the fourth quarter, up 25% from the previous quarter, the WSJ reports . That was higher than analysts expected,

the paper says. The company said it expects “modest quarter-over-quarter growth while we focus on bringing additional clinics on board.” Regulating Transplants: The government’s Health Resources Services Administration is proposing to regulate transplants of faces, hands and voice boxes — among other less-transplanted body parts — as it does other organs, the Associated Press reports . That would move those transplants into the United Network for Organ Sharing (UNOS) system and would mark “a big step toward expanding access to these radical operations,” the AP says. Last week physicians reported the details of three full-face transplants performed in 2011 at Brigham and Women’s Hospital. Image: iStockphoto

More: 
A.M. Vitals: Lilly Sees a Profit Drop of Up to 20% in 2012